Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.4 HKD | +0.16% | -0.31% | -65.99% |
03-27 | Cryofocus Medtech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-15 | Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-65.99% | 195M | - | ||
+40.73% | 739B | C+ | ||
+31.00% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+14.89% | 240B | B+ | ||
+9.33% | 210B | B- | ||
-5.19% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6922 Stock
- Ratings Cryofocus Medtech (Shanghai) Co., Ltd.